Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning.
about
Follicular lymphoma: 2012 update on diagnosis and managementFollicular lymphoma: 2011 update on diagnosis and managementFollicular lymphoma: 2014 update on diagnosis and managementHematopoietic cell transplantation for B-cell lymphoma: an updateAllogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older PatientsThe Role of Autologous and Allogeneic Stem Cell Transplantation in Follicular Lymphoma in The New Drugs EraReappraising the timing of transplant for indolent non-Hodgkin lymphomas.Fludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trialAllotransplantation for patients age ≥40 years with non-Hodgkin lymphoma: encouraging progression-free survival.Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphomaImmunomodulatory nonablative conditioning regimen for B-cell lymphoid malignanciesReduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials.Introduction to the reports from the National Cancer Institute First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response.Unrelated donor hematopoietic cell transplantation for non-hodgkin lymphoma: long-term outcomes.Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901(90)Y-ibritumomab tiuxetan followed by reduced-intensity conditioning and allo-SCT in patients with advanced follicular lymphoma.Histology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogeneic hematopoietic cell transplantation.A new approach for eradication of residual lymphoma cells by host nonreactive anti-third-party central memory CD8 T cellsPhase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantationControversies and recent advances in hematopoietic cell transplantation for follicular non-hodgkin lymphomaAllogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning.Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning.Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma.Long-term outcome after autologous or allogeneic stem cell transplantation in patients with recurrent follicular lymphoma.Superior long-term outcome of patients with early transformation of non-Hodgkin lymphoma undergoing stem cell transplantationAllogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders.Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party.Hematopoietic stem cell transplantation for the management of follicular lymphomaOutcomes of autologous or allogeneic stem cell transplantation for non-Hodgkin lymphoma.Non-myeloablative allogeneic hematopoietic stem cell transplantation.Role of hematopoietic stem cell transplant in the management of follicular lymphoma.Transplantation for non-Hodgkin lymphoma.Follicular lymphoma: the case for timely intervention.Allogeneic immunotherapy to optimize the graft-versus-tumor effect: concepts and controversies.Relapse after allogeneic stem cell transplantationFollicular lymphoma: emerging therapeutic strategies.Stem cell transplantation for indolent lymphoma and chronic lymphocytic leukemia.Stem cell transplantation for indolent lymphoma: a reappraisal.Allogeneic stem cell transplantation in follicular lymphoma.
P2860
Q22252956-B9832DF6-6750-4D9B-B78D-843E93208D21Q26851450-D2E2AC37-DB54-492F-8FE6-BEDEB5C7542DQ27021850-87BD3E36-DC87-4640-91E6-E59E3EC37952Q27026617-E37459CC-C697-4ECA-B834-2A04B29606DEQ28066710-79A9B88B-2D98-42CE-AB6C-6761F905EF09Q28072397-9925AACC-9620-4039-8943-21A1C7FBE8DCQ30248407-B6903635-5202-4454-A808-04EAD09E815AQ30543777-ED56CD43-4C0D-490F-AD67-FE805EC72171Q33756719-866B11BC-2713-4CBC-A4B9-BB1E65B1362DQ33792160-69ACEFB8-552E-490C-9254-B321ABC3025BQ33795160-CFDA55A7-B51F-4AAA-AAA8-CC0565C01BEFQ33952823-63A79AB7-C9F1-495C-A4AF-11521AC18FDCQ34378623-ADB2E2CE-8569-4EE2-9966-D81FC711A62FQ35043077-EB93B15F-D1BB-4C2B-BDED-186189DF1B0FQ35061893-702D706E-A0B3-45B3-BE68-E59037806CEDQ35100217-B2B4ADB0-78AB-423F-A6D3-7FFB124AE3AFQ35115650-287BCBB8-D361-4FFD-AE71-B038A764801FQ35223780-5222EFB3-82D2-40D0-AA57-69471956160AQ35743874-3EEB6317-27D9-40ED-A89E-8A383E8B1345Q36176670-54F490A3-7D69-487E-8928-694DBC710AF9Q36336614-5527FDCA-FE19-4F1F-918A-6723A41DCFC6Q36426327-53336EEC-8288-4685-B2C2-B254CE5E96A3Q36570651-5CCDADFF-E575-4466-8DAE-9A3CD97BEB6CQ36834194-99FBE2F3-8E5A-47CD-8F52-251146145F8CQ36837761-3CDA157F-0845-42CE-8FE0-B793E0041932Q36837765-46BE57BF-309A-4B67-A193-03E2759935A7Q36928725-AC9087D5-53AE-45A6-9C8A-8DFFF91772A2Q36967098-EE1968AB-791D-4868-B53E-679336E6A6E0Q37194061-0D873FC3-C3B2-483C-9CE5-C9854E84F946Q37212916-8507FE3B-F2A7-46EF-86F1-77558AFDFC1DQ37308127-68F13F3B-FFF8-4AF2-9341-C7D63A4F8765Q37533977-97519891-BAE3-46F1-8C30-7BC191F67FF7Q37810079-DBE5AD64-83F8-4093-8A13-6BE9241843C2Q37810093-738E97FD-E85E-424D-9679-C2003C273717Q37810098-EDFBD6D2-8774-40ED-9CC6-A8CA7639907DQ37810125-089EEEC3-3E58-4B3E-8EDF-4B331DA51A85Q37810129-A54A5E35-4809-4A18-9940-30611569A5C2Q37824996-2E51ABBD-2DB7-4957-8F96-48A8C26C794FQ37884884-66FF0061-5D0F-44B9-B310-30B8188A991FQ37887151-C0F219ED-1DF3-4465-A166-63C57D192012
P2860
Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Allogeneic transplants in foll ...... to myeloablative conditioning.
@en
type
label
Allogeneic transplants in foll ...... to myeloablative conditioning.
@en
prefLabel
Allogeneic transplants in foll ...... to myeloablative conditioning.
@en
P2093
P2860
P50
P1476
Allogeneic transplants in foll ...... to myeloablative conditioning.
@en
P2093
Brian J Bolwell
Charles F Lemaistre
Christopher N Bredeson
César O Freytes
David I Marks
David J Inwards
Dipnarine Maharaj
Gregory A Hale
Harry C Schouten
Jeanette Carreras
P2860
P304
P356
10.1016/J.BBMT.2007.11.004
P577
2008-02-01T00:00:00Z